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Objective: We studied the effects of the transient activation of parathyroid hormone (PTH)/PTH-related
peptide (PTHrP) signaling during the repair of 5-mm-diameter full-thickness defects of articular cartilage
in the rabbit.
Materials and methods: Cylindrical full-thickness articular cartilage defects of 5 mm in diameter were
artiﬁcially created in the femoral trochlea of male adolescent Japanese white rabbits using a hand-drill.
Recombinant human PTH(1-84) was then administered into the joint cavity continuously or intermit-
tently for 2 weeks post-injury. The reparative tissues were histologically examined at 2, 4, and 8 weeks,
and were also immunohistochemically examined for type II collagen. Double immunostaining analysis
was also performed for the PTH/PTHrP receptor and proliferating cell nuclear antigen (PCNA) in the
regenerating tissues.
Results: No evidence of cartilage formationwas evident throughout the period of the experiments in injured
animals administered saline alone. In contrast, cartilage formation occurred at 4 weeks in both the contin-
uous and intermittent PTH-treated defects. At 8weeks post-injury, for the intermittently treated defects, the
regenerated cartilage successfully resurfaced the defects and the original bone-articular cartilage junction
was recovered. In contrast, the defects were covered with ﬁbrous or ﬁbrocartilaginous tissues in the
continuously administered group. PCNA and PTH/PTHrP receptor-double positive mesenchymal cells were
signiﬁcantly increased in both the continuous and intermittent PTH-treated defects at 2 weeks post-injury.
Conclusions: The present results suggest that the transient activation and release from PTH/PTHrP
signaling during the early stages of the cartilage repair process facilitates the induction of regenerative
chondrogenesis in full-thickness articular cartilage defects.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Cartilage is a typical avascular tissue and thus has a very limited
capacity for regenerative repair. Full-thickness defects that penetrate
articular cartilage and subchondral bone extending into marrow
cavity undergo a repair process that eventuallyﬁlls the defect cavities
with ﬁbrous, ﬁbrocartilaginous, or hyaline cartilaginous tissue,
depending on the location and size of injury1,2. In a mature rabbit
model, no chondrogenic repair response occurs for large cylindrical
defects (5 mm in diameter) created in the femoral trochlea. In
addition, only ﬁbrous tissue has been shown to ﬁll these defect
cavities3. In contrast, smaller cylindrical defects (3 mm indiameter)o: Y. Hiraki, Department of
Sciences, Kyoto University, 53
an. Tel/Fax: 81-75-751-4633.
iraki).
s Research Society International. Pare spontaneously repairedwith regenerated hyaline cartilage3. Bone
marrow-derived chondroprogenitor cells have anessential role in the
chondrogenic repair of the full-thickness defects of articular
cartilage2e4.
Various bioactive molecules, such as growth/differentiation
factors and hormones, participate in the regulation of repair
response in the defects5. Among these molecules, ﬁbroblast
growth factor-2 (FGF-2) plays an important role in the induction
of the chondrogenic repair response in cartilage defects by stim-
ulating the mobilization and recruitment of proliferating chon-
droprogenitor cells into the defect cavities, resulting in
resurfacing the 5-mm-diameter defects via the regeneration of
hyaline cartilage4,6,7. Hence, size limitations to the chondrogenic
repair response in these types of cartilage defects can be alleviated
by the addition of exogenous FGF-24. When endogenous FGF-2
activity is neutralized by monoclonal antibodies, no chondro-
genic repair response occurs even in the 3-mm-diameter defects,
which are ﬁlled and resurfaced by ﬁbrous tissue only3.ublished by Elsevier Ltd. All rights reserved.
Table II
Histological grading system for articular cartilage healing (the O’Driscoll score)*
Score
Nature of the predominant tissue
Cellular morphology
Hyaline articular cartilage 4
Incompletely differentiated mesenchyme 2
Fibrous tissue or bone 0
Safranin-O staining of the matrix
Normal or nearly normal 3
Moderate 2
Slight 1
None 0
Structural characteristics
Surface regularity
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peptide (PTHrP) signaling inhibits the differentiation of chon-
droprogenitor cells that are recruited to reparative tissue in cartilage
defects8. The local administration of human PTH(1-84) completely
disrupts the differentiation of chondroprogenitor cells in 3-mm-
diameter defects. There have been no adverse effects detected in the
preceding steps for chondrogenesis upon exposure to PTH, i.e., the
migration and proliferation of PTH/PTHrP receptor-positive chon-
droprogenitor cells. Chondrogenesis resumes when the defects are
released from inhibitory PTH/PTHrP signaling during the early phase
of repair at 2 weeks post-injury9. Mesenchymal cells that migrate to
the site of repair have been found to be chondrogenesis-competent
for only a limited time-span of around 2 weeks, but they lose their
chondrogenic capacity after prolonged PTH treatment for 4 weeks.
Most of the cells in the reparative tissue are PTH/PTHrP receptor-
negative. Thus, 3-mm-diameter small defects continuously treated
with PTH for 4 weeks are never covered with cartilage9.
In our present study, we examined the effects of the transient
activation and release from PTH/PTHrP signaling upon the repair
response in 5-mm-diameter large full-thickness defects of articular
cartilage in the rabbit. Our results indicate that the intermittent
administration of PTH successfully induces the chondrogenic repair
response in these defects and will be beneﬁcial for the regenerative
repair of large full-thickness defects of articular cartilage.
Materials and methods
Creation of full-thickness defects of articular cartilage in rabbits
Male adolescent Japanese white rabbits (n¼ 55), weighing
3e3.4 kg, were anaesthetized with sodium pentobarbital (30 mg/kg
body weight intravenously). The right knee joint was then opened
using amedial parapatellar approachunder sterile conditions and the
patella was dislocated laterally to expose the articular surface of the
femoral trochlea. Full-thickness defects (5 mm in diameter; 4 mm in
depth) were created in the weight-bearing area of the femoral
trochlea with a hand-drill equipped with a 5-mm-diameter drill-bit,Table I
Scoring system for the histological appearance of full-thickness defects of articular
cartilage*
Characteristics Score
Filling of defects (%)
125 3
100 4
75 3
50 2
25 1
0 0
Reconstitution of osteochondral junction
Yes 2
Almost 1
Non close 0
Cell morphology
Normal 4
Mostly hyaline and ﬁbrocartilage 3
Mostly ﬁbrocartilage 2
Some ﬁbrocartilage, but mostly non-chondrocytic cells 1
Non-chondrocytic cell only 0
Matrix staining
Normal 4
Reduced staining 3
Signiﬁcant staining 2
Faint staining 1
No staining 0
Perfect score 14
* Modiﬁed from Pineda et al. (1992)11.as described previously3,8. All animals were allowed to walk freely
without a splint. Our research protocol was approved by the animal
ethics committee of Kumamoto University School of Medicine, and
animal care and experimental procedures were conducted in accor-
dance with institutional guidelines (http://card.medic.kumamoto-u.
ac.jp/card/japanese/kisoku/kisoku.html).
Administration of human parathyroid hormone 1-84 [hPTH(1-84)]
Recombinant hPTH(1-84) was expressed and puriﬁed from
Escherichia coli by high-performance liquid chromatography using
a cleavable fusion protein strategy as previously described10. Puri-
ﬁed hPTH(1-84) prepared in this way was supplied by Chugai
Pharmaceuticals (Tokyo, Japan) for the present study. The animals
were ﬁtted with an osmotic pump (Alzet, Model 2002, Alza Corp.,
Palo Alto, CA) connected to silastic medical grade tubing (0.75 mm
inside diameter/1.45 mm outside diameter). A 5-mm-long piece of
tubing was then introduced into the articular knee cavity through
the articular capsule. An osmotic pump was then placed subcuta-
neously into the hind region of the leg and the articular capsule and
skin were closed independently with 4-0 nylon sutures3,8.
Fifty-ﬁve rabbits were given 5-mm-diameter defects and then
divided into three experimental groups; one group was treatedIntact 3
Superﬁcial horizontal lamination 2
Fissures e 25e100% of the thickness 1
Severe disruption including ﬁbrillation 0
Structural integrity
Normal 2
Slight disruption, including cysts 1
Severe disintegration 0
Thickness
100% of normal adjacent cartilage 2
50e100% of normal cartilage 1
0e50% of normal cartilage 0
Bonding to the adjacent cartilage
Bonded at both ends of graft 2
Bonded at one end, or partially at both ends 1
Unbonded 0
Freedom from structural changes of degeneration
Hypocellularity
Normal cellularity 3
Slight hypocellularity 2
Moderate hypocellularity 1
Severe hypocellularity 0
Chondrocyte clustering
No clusters 2
<25% of the cells 1
25e100% of the cells 0
Freedom from degenerative changes in adjacent cartilage
Normal cellularity, no clusters, normal staining 3
Normal cellularity, mild clusters, moderate staining 2
Mild or moderate hypocellularity, slight staining 1
Severe hypocellularity, poor or no staining 0
* O’Driscoll et al. (1988)12.
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group, n¼ 15), one group was treated with PTH intermittently for 2
weeks after injury (the intermittent PTH group, n¼ 15), and we
analyzed an untreated control group (n¼ 20) which received saline
alone for 2 weeks. In some experiments, additional untreated
control rabbits (n¼ 5) which received saline for 1 week were
sacriﬁced and subjected to histological analysis at 1 week post-
injury. PTH was dissolved in sterile saline at a concentration of
50 mg/ml. The PTH solution was used in the continuous and inter-
mittent PTH group. For animals in the continuous PTH group, the
osmotic pumps were ﬁlled with 200 ml of sterile saline containing
human recombinant PTH (50 mg/ml) and had a nominal pumping
rate of 0.5 ml/h for 2 weeks. For animals in the intermittent PTH
group, the osmotic pumps ﬁlled with sterile saline were connected
to a length of tubing that had been precharged with the intermit-
tent administration program. The program consisted of alternating
segments of 5 ml PTH (50 mg/ml) solution and 5 ml sterile saline
interrupted by 1 ml air bubbles. As saline from the pump gradually
displaced the contents of the tubing, precharged PTH solution or
sterile saline were alternatively discharged from the opposite end
of the tubing. This pumping system results in the administration of
the hormone solution for 10 h with a 14-h-interval. The animals
were thus given an intermittent administration of PTH for 2 weeks
post-injury. In all experimental group, the implanted osmotic pump
and tubing were removed at 2 weeks after creation of the defects.
Histological and immunohistochemical analyses
Five animals from each study group were sacriﬁced at each time
point with an overdose of sodium pentobarbital. The distal portionFig. 1. The effects of the limited treatment of PTH on the repair of 5-mm-diameter articular c
with saline alone (A, D, and G), continuously with 25 ng/h hPTH(1-84) for (B, E, and H), or int
initial 2 weeks post-injury. The distal portion of each femur was cut in the transverse plane
weeks (GeI) after the creation of the defects. Bar, 500 mm.of each femur was then ﬁxed in 4% paraformaldehyde at room
temperature for 1 h, decalciﬁed with 10% EDTA for 3 weeks and
then embedded in parafﬁn for subsequent histological analysis. To
examine the sequential repair processes in each cavity, 5 mm
transverse sections were cut in the transverse plane. The sequential
repair process of each group was histologically analyzed as previ-
ously reported8,9. For semi-quantitative analysis of the reparative
tissue, the sections were examined in a blind manner by two
observers, and were scored according to the modiﬁed Pineda scale
(Table I)11 and the O’Driscoll score (Table II)12. The modiﬁed Pineda
scale used was inversely correlated to the original one so that
a better recovery of the articular structure had a higher score. The
score ranged from 0 (worst) to 14 (best). For quantiﬁcation of
subchondral bone repair, the cross-sectional area of the sub-
chondral bone in the defects was measured. The section that had
the maximum diameter (5 mm) was chosen as the representative
section for each animal. The images were captured as digitized
images with a scanner and stored on a personal computer. Both
edges of the defect on the surface and a perpendicular (5 mmwide
and 4 mm deep) rectangular region (original defect area) were
delineated on the digital images, which were processed using
Adobe Photoshop 3.0 to exclude cartilage, ﬁbrous tissues and bone
marrow. The cross-sectional area of bone within the original defect
was determined using National Institutes of Health (NIH) image
version 1.6 image analysis software (NIH, Bethesda, MD). The cross-
sectional area of the subchondral bone was expressed as the mean
and 95% conﬁdence interval of ﬁve animals from each experimental
group.
The presence of type II collagen in reparative tissues was exam-
ined immunohistochemically using a mouse monoclonal antibodyartilage defects in rabbits for the initial 2 weeks post-injury. These defects were treated
ermittently (10 h/day with a 14-h interval) with 25 ng/h hPTH(1-84) (C, F, and I) for the
and the sections were stained with safranin-O at 2 weeks (AeC), 4 weeks (DeF), and 8
Fig. 2. Histological scores for the reparative 5-mm-diameter cartilage defects treated
according to the modiﬁed Pineda scale (Table I). Values are the means and 95%
conﬁdence interval of the scores from the histological sections of ﬁve individual
animals. In (A), total histological scores at 2, 4 and 8 weeks post-injury were compared.
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antibody cross-reacts with rabbit type II collagen13. The parafﬁn
sections were deparafﬁnized and hydrated, and endogenous
peroxidase activity was blocked by 0.5% hydrogen peroxide in
methanol, followed by washing with 0.1% bovine serum albumin
(BSA) in Tris-buffered saline (TBS). The sections were then treated
with 500 U/ml testicular hyaluronidase (Sigma Chemical Co.,
St Louis, MO)14. Non-speciﬁc staining was reduced by incubation
with horse serum. The sections were incubated with the primary
antibody (dilution 1:100) overnight at 4C, treated with the
Vectastain avidinebiotineperoxidase complex (ABC) kit (Vector
Laboratories, Burlingame, CA), reactedwith diaminobenzidine (DAB)
solution, and then counterstained with hematoxylin.
The expression of PTH/PTHrP receptor protein in the reparative
tissue was examined using a mouse monoclonal antibody raised
against the opossum PTH receptor (Berkley antibody Co, Richmond,
CA) using the same protocol described above9. The speciﬁcity and
cross-reactivity of the monoclonal antibody to the rabbit PTH
receptor were conﬁrmed using the rabbit kidney and growth plate
as a positive control [Fig. 5(E)], and the rabbit prostate [Fig. 5(F)] and
thyroid gland [Fig. 5(G)] as a negative control9. The sections were
counterstained with methyl green. The relationship between
PTH/PTHrP receptor expression and cell proliferationwas evaluated
by double immunostaining for PTH/PTHrP receptor and prolifer-
ating cell nuclear antigen (PCNA). The parafﬁn sections were
immunostained ﬁrst for PTH receptor as described above, washed in
0.1% BSA in TBS and the sections were incubated with a monoclonal
antibody against PCNA (dilution 1:100; Dakopatts, Copenhagen,
Denmark) at room temperature for 1 h. They were next washed in
0.1% BSA in TBS and incubated with alkaline phosphatase (ALP)
conjugated secondary antibody (dilution 1:100; Sigma, St. Louis,
MO) for a further hour. The color development of the ALP reaction
was carried out using ALP substrate kit I (Vector Red; Vector
Laboratories, Burlingame, CA). A 1 mM solution of levamisole
(Vector Laboratories) was added to block endogenous ALP activities.
The sections were then counterstained with methyl green.
Quantitative analysis of the co-localization of PCNA and PTH/PTHrP
receptor
To characterize reparative tissue immunohistochemically, we
analyzed the cells in this tissue by dividing them into four sub-types:
PTH/PTHrP receptor single-positive, PCNA single-positive, PTH/
PTHrP receptor/PCNA double-positive and double-negative. Each
sub-type was quantiﬁed according to the method of Aizawa and
expressed as the percentage of the total number of cells in the
defects15,16. A section of each defect was then divided into 12
sampling square areas (1 mm 1 mm) in which ﬁve ﬁelds were
selected at a magniﬁcation of 400. Because three sections from
each parafﬁn bloc were used, the numbers of each of the four sub-
types of spindle-shaped cells were determined in a total of 180
ﬁelds for each animal. The incidence of each cell type in the each case
of reparative tissue was expressed as the mean and 95% conﬁdence
interval for ﬁve animals from each experimental group. Sections
were examined in a blind manner.*Signiﬁcant difference from control, P< 0.05. To evaluate cartilaginous repair in the
induced defects, scores for cell morphology and matrix staining were performed as
shown in (B) and (C), respectively. Continuous PTH-treated defects showed higher
scores compared to the control at 4 weeks (P¼ 0.0219) in the total score. Intermittent
PTH-treated defects showed higher scores compared to the control at 4 (P¼ 0.0219)
and 8 weeks (P¼ 0.0153) in the total score. In the cell morphology, the continuous and
the intermittent PTH-treated defects showed higher score compared to the control at
8 weeks (control vs continuous PTH-treated defect P¼ 0.0203, vs intermittent PTH-
treated defect P¼ 0.0062). In the matrix staining, the both PTH-treated defects also
showed higher score compared to the control at 8 weeks (control vs continuous PTH-
treated defect P¼ 0.0486, vs intermittent PTH-treated defect P¼ 0.0025).
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Results were expressed as mean and 95% conﬁdence intervals.
Statistical signiﬁcance was estimated using ManneWhitney’s
U test. A P value of <0.05 was considered statistically signiﬁcant.
Results
Histological features during the repair of articular cartilage defects
Large cylindrical full-thickness articular cartilage defects (5 mm
in diameter) are not resurfaced with hyaline-like cartilage sponta-
neously, but ﬁlledwith ﬁbrous tissue only1e3. Control defects treated
with saline alone were initially ﬁlled with blood clots but contained
undifferentiated ﬁbroblast-like cells within 2 weeks [Fig. 1(A)].
Although there was no sign of cartilaginous repair in these saline-
treated defect cavities [Fig. 2(B and C)], appositional repair of
subchondral bone had already commenced by 2 weeks post-injury
(Table III). At 8 weeks, the subchondral bone was almost
completely reconstituted (Table III), but the defects were surfaced
only byﬁbrous tissue [Fig.1(G)]. No safranin-O stainingwasdetected.
In defect cavities that had been continuously administered with
25 ng/h hPTH(1-84) for the initial 2 weeks post-injury [Fig. 1(B)] or
had been administered intermittently with a-10-h administration
of 25 ng/h hPTH(1-84) followed by a 14-h-interval during this same
period [Fig. 1(C)], no apparent sign of chondrogenesis could be
observed by histological appearance, similar to the saline-treated
control defects [Figs. 2 and 3]. The subchondral bone area in
either case of PTH administration at 2 weeks post-injury appeared
to be smaller than that of the control defects, but similar to that of
the control defects at 1 week after injury (Table III). This was not
statistically signiﬁcant however.
In the animal groups that had been continuously treated or
intermittently treated with PTH for the initial 2 weeks, chondro-
genesis was evident in the defect cavities by 4 weeks post-injury. In
both groups also, the defects contained similar amounts of safranin-
O positive cartilaginous repair tissue on the subchondral bone
[Fig. 2(E and F)]. Though the predominant tissue was ﬁbrocartilage
at the surface, the reparative tissue at the center of the defects
contained chondrocytic cells of a rounded or polygonal shape
[Figs. 2(B) and 3(B)] suggesting that short-term PTH treatments
successfully stimulate chondrogenesis in the reparative tissue of
5-mm-diameter cartilage defects.
In the animal group treatedwith PTH continuously for the initial
2 weeks, the cartilaginous repair response could not be maintained
at 8 weeks post-injury. Reduced safranin-O staining was seen in the
reparative tissue covering the defects treated with continuous PTH
at 8 weeks [Fig. 1(H)]. Moreover, most cells in the reparative tissue
were poorly differentiated mesenchyme and there was little type II
collagen immunoreactivity, with the exception of the deeper layer
facing the regenerated subchondral bone surface [Fig. 4(D)].
Round-shaped chondrocytic cells were also only observed in the
reparative tissue near to the subchondral bone. Surface laminationTable III
Time course of subchondral bone area (mm2) in the histological sections during repair o
1 week 2 weeks
Saline alone 3.14 (2.63, 3.62) 4.02 (3.63, 4.41)
hPTH(1-84)
Continuous e 2.71 (1.52, 3.91)
Intermittent e 3.05 (1.31, 4.79)
Photomicrographs were taken of the histologic sections and scanned on a digital scanne
bone in the defects using NIH image. Data are represented as amean and 95% conﬁdence i
the groups.was further observed in these continuously treated defects at 8
weeks. The total modiﬁed Pineda score of the continuous PTH
treatment group at 8 weeks was similar to that of the control group
treated with saline alone (P¼ 0.1745), though signiﬁcant
improvements were seen in cell morphology (P¼ 0.0203) and
matrix staining (P¼ 0.0486) [Fig. 2(AeC)]. The overall O’Driscoll
score of the continuous PTH treatment group was also similar to
that of the control group at 8 weeks (P¼ 0.1337) [Fig. 3(A)]. The
score for nature of the predominant tissue [Fig. 3(B)], which
includes cellular morphology and safranin-O staining of the matrix,
was signiﬁcantly higher (P¼ 0.0486) in the continuous PTH treat-
ment group, compared to the control group at 8 weeks.
In contrast to continuous treatment, the defects intermittently
treated with PTH were successfully covered with hyaline-like
cartilage by 8 weeks post-injury and the degree of safranin-O
staining was comparable to that seen in the original articular
cartilage [Fig. 2(I)]. As shown in Fig. 4(F), type II immunoreactivity
could also be seen abundantly throughout the resurfacing cartilage,
which was smoothly connected with the original type II-collagen
positive articular cartilage. The average modiﬁed Pineda score
was also signiﬁcantly higher than that of the control (total score:
P¼ 0.0153, cell morphology: P¼ 0.0062, matrix staining: P¼ 0.025)
[Fig. 2(AeC)]. Similar results were observed when the histological
samples were scored using the O’Driscoll score (total score:
P¼ 0.0189, nature of the predominant tissue: P¼ 0.0104)
[Fig. 3(A and B)]. While the scores of the structural characteristics
and the freedom from cellular changes of degeneration for the
intermittent PTH treatment group were higher than those of
control at 8 weeks, the differences were not statistically signiﬁcant
[Fig. 3(C and D)]. No signiﬁcant difference in the degenerative
changes of the adjacent cartilage was observed between any of the
groups throughout the experimental period [Fig. 3(E)].
Chondrogenic responses in the defect cavities
In the control cartilage defects treated with saline alone, the
expression of PCNA was only found in mesenchymal cells deeply
located at the periphery of the defects (near to the subchondral bone
surface) at 2 weeks post-injury. Most of the cells ﬁlling these saline-
treated defects were PCNA-negative. The incidence of PCNA-positive
cells was also below 20% on average in the control group (Table IV)
and PTH/PTHrP receptor-positive cells were detectable only at the
periphery of the defects, many of which were also PCNA-positive. In
contrast, PTH/PTHrP receptor single-positive cells were widely
evident in the center of the control defects, where only a few cells
were PCNA-positive [Fig. 5(B), right-hand side]. Hence, PCNA and
PTH/PTHrP receptor-double positive cells were found almost exclu-
sivelyat theperipheryof thedefects near the subchondral bone in the
control group [Fig. 5(B), the left-hand side].
In contrast, PCNA-positive cells were frequently and almost
uniformly detected in the PTH-treated defects, irrespective of
whether the hormone was administered continuously or inter-
mittently. Over 40% of cells in the reparative tissue were PCNA-f full-thickness articular cartilage defects
4 weeks 8 weeks 24 weeks
7.30 (6.66, 7.94) 8.88 (8.21, 9.54) 8.92 (7.26, 10.59)
6.03 (5.42, 6.64) 8.05 (6.88, 9.22) e
6.95 (5.39, 8.50) 9.35 (8.21, 10.46) e
r. The computerized images were analyzed for cross-sectional area of subchondral
nterval of themean (n¼ 5 for each group). There was no signiﬁcant difference among
Fig. 3. Histological scores for the reparative 5-mm-diameter cartilage defects according to the O’Driscoll score (Table II). Values are the means and 95% conﬁdence interval of the
scores from the histological sections of ﬁve individual animals. In (A), total histological scores at 2, 4 and 8 weeks post-injury were compared. *Signiﬁcant difference from control,
P< 0.05. To evaluate cartilaginous repair in the induced defects, scores for nature of the predominant tissue, which includes cellular morphology and safranin-O staining of the
matrix, was performed as shown in (B). Continuous PTH-treated defects showed higher scores compared to the control at 4 weeks (P¼ 0.0439) in the total score. Intermittent PTH-
treated defects showed higher scores compared to the control at 4 (P¼ 0.0472) and 8 weeks (P¼ 0.0189) in the total score. In the nature of the predominant tissue, the continuous
and the intermittent PTH-treated defects showed higher score compared to the control at 8 weeks (control vs continuous PTH-treated defect P¼ 0.0132, vs intermittent PTH-treated
defect P¼ 0.0318). There was no signiﬁcant difference among the group in the structural characteristics (C), the freedom from cellular changes of degeneration (D) at 8 weeks.
During all of the experimental period, no signiﬁcant difference in the freedom from degenerative changes in adjacent cartilage was observed between any of the groups (E).
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mittently at 2 weeks post-injury (Table IV), although no apparent
difference in the cell density and the percent ﬁlling of the defects
became evident in any of the experimental groups at the end of the
PTH treatment at 2 weeks. It is noteworthy that most ofundifferentiated cells in the PTH-treated defects were PTH/PTHrP
receptor-positive. Numerous PCNA and PTH/PTHrP receptor-double
positive cells are thus uniformly present throughout the reparative
tissue in cartilage defects treated continuously or intermittently
with PTH [Fig. 5(D)].
Fig. 4. Immunohistochemical analysis of type II collagen at 8 weeks post-injury in
saline-treated control defects (A, B), defects treated with PTH continuously (C, D) or
defects treated with PTH intermittently (E, F). Safranin-O (A, C, E) and type II collagen
immunostaining (B, D, F) were carried out. Arrows indicate the boundary between the
original articular cartilage (right) and the reparative tissue (left). A positive immunore-
activity for type II collagenwas observed throughout the reparative tissue in the defects
intermittently treated with PTH. Bar, 1.25 mm for A, C, and E, 500 mm for B, D, and F.
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Our present study showed that continuous and intermittent
short-term PTH treatments in early stage of repair successfully
induced chondrogenesis in the reparative tissue of 5-mm-diameter
full-thickness articular cartilage defects. We also demonstrated that
the defects treated with intermittent administration of PTH wereTable IV
Cellularity and proliferation of the undifferentiated mesenchymal cells at 2 weeks after
All nuclei were counted in a total of 96 ﬁelds in the 5-mm-diameter defects at 2weeks using
Methods. The PCNA-positive and -negative cells were counted in a total of 240 ﬁelds in th
ﬁcation of 400. Data are represented as amean and 95% conﬁdence interval of themean. A
cells between the control (saline alone) and the continuous PTH treated defects (P ¼ 0.028repaired with hyaline-like cartilage by 8 weeks as similar to FGF-2-
treated 5-mm-diameter full-thickness articular cartilage defects.
However, when compared with FGF-2-treated defects, chondro-
genesis in the PTH-treated defects was slightly delayed. In PTH-
treated defects, there was no evidence of chondrogenesis at 2
weeks post-injury, whereas cartilage formation became evident as
early as 2 weeks in FGF-2-treated 5-mm-diameter defects3,4.
The bone marrow contains stem cells that can differentiate into
multiple mesenchymal lineages17e19. The recruitment of marrow-
derived PTH/PTHrP receptor-positive chondroprogenitor cells and
their subsequent proliferative expansion plays an important role in
inducing the cartilaginous repair of full-thickness defects of articular
cartilage, as previously reported4,20,21. In the rabbit model of these
injuries, 5-mm-diameter large defects have been found to require
supplementation of exogenous growth factors such as FGF-2 to evoke
a chondrogenic repair response in defect cavities3,6,7. In addition, the
accumulation of PCNA-positive cells in the PTH/PTHrP receptor-
positive mesenchymal cell population in an early phase of the
repair process was indicative of subsequent overt chondrogenesis at
a later stage of repair4,9. Hence, we analyzed the accumulation of
proliferating chondroprogenitor cells by double immunostaining for
the PCNA and PTH/PTHrP receptor in our current experiments. The
present results of double immunostaining showed signiﬁcant
increase of PCNA and PTH/PTHrP receptor-double positive mesen-
chymal cells in both continuous and intermittent PTH-treateddefects
at 2 weeks post-injury. These double positive cells were uniformly
detected throughout the defects treated with continuous or inter-
mittent PTH administration. These observations suggest that PTH
treatment for an initial 2 weeks facilitates the recruitment of prolif-
erating chondroprogenitor cells to the repair site.
It is known that PTHrP is secreted primarily by resting chon-
drocytes at the top of cartilaginous bone precursors and in the
perichondrium of developing embryos, and acts on proliferating and
prehypertrophic chondrocytes through the PTH/PTHrP receptor to
slow the rate of chondrocyte differentiation22e24. However, recent
animal studies have suggested that there are positive actions of PTH
upon bone fracture healing and repair25e27. Using a rat fracture
model, Nakazawa et al. have reported that daily subcutaneous
injections of PTH stimulate chondrogenesis through the enhanced
proliferation of mesenchymal cells28. Our present results are
consistent with their contention that PTH increases proliferation of
chondroprogenitor cells in the early stages of chondrogenesis, but not
chondrocytes28.
On the other hand, the sustained activation of PTH/PTHrP
signaling clearly inhibits the differentiation of chondroprogenitor
cells8,29. The continuous local administration of PTH was found
previously to completely inhibited cartilage formation, even in the
3-mm-diameter smaller defects and despite an apparentcreation of defects
three section for each animal at amagniﬁcation of 200, as described inMaterial and
e 5-mm-diameter defects at 2 weeks using three sections for each animal at a magni-
sterisks (*) signify a statistical signiﬁcant difference in the incidence of PCNA-positive
3) and between the control and the intermittent PTH treated defects (P ¼ 0.009).
Fig. 5. Double immunostaining for PCNA and PTH/PTHrP receptor at 2 weeks post-
injury in the rabbit cartilage defect model, revealing mesenchymal cells in the upper
left of the defects treated with saline alone (A, B) and treated with PTH intermittently
(C, D). The transverse sections of femoral trochlea were stained with Safranin-O (A, C)
or with PCNA and PTH/PTHrP receptor antibodies (B, D). PCNA was stained red with
ALP substrate kit I, and PTH/PTHrP receptor was stained brown with
immunoperoxidase-DAB. Panels B and D represent the PCNA or PTH/PTHrP receptor-
positive cells in the corresponding areas denoted by asterisks in panels A and C,
respectively. Bar, 1.25 mm for A and C, 50 mm for B and D. Panels E, F, and G show the
single immunohistochemical staining of PTH/PTHrP receptor. The rabbit growth plate
(E) was used as positive control and the rabbit prostate (F) and the rabbit thyroid gland
(G) were used as negative control. Bar, 30 mm for E, 100 mm for F and G.
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cavities during the early stages of repair8. Accumulated chon-
droprogenitor cells remain chondrogenesis-competent for at least 2
weeks in the defect cavities, but lose this ability by 4 weeks after the
creation of cartilage defects9. We thus speculate from these earlier
ﬁndings and our present experimental setting that reparative tissue
has to be released from PTH/PTHrP signaling so that accumulated
proliferating chondroprogenitor cells can resume the process of
differentiation into chondrocytes.
We observed cartilage formation in both of our PTH-treated
animal groups at 4 weeks post-injury [Figs. 1, 2, and 3]. However,
only the defects intermittently treated with PTH showed resurfac-
ing by hyaline-like cartilage. The continuously PTH-treated defects
were covered with ﬁbrous or ﬁbrocartilaginous tissues at 8 weeks
[Figs. 1 and 4]. The mechanisms underlying this differential repair
outcome remain unknown. The molecular mechanism by which
PTH promotes chondrogenesis in full-thickness defects of articular
cartilage needs to be further explored in future studies.
The anabolic bone effects of PTH administration are well estab-
lished. Intermittent PTH administration is also an approved treat-
ment for enhancing bone mass in osteoporosis patients. Recent
studies have strongly argued that the Wnt signaling pathway
participates in the anabolic effects of PTH on bone formation andfracture repair30e32. However, neither the continuous nor intermit-
tent administration of PTH in our current study produced a statisti-
cally signiﬁcant difference in the time course of subchondral bone
reconstitution (Table III). This suggests that the chondrogenic effects
of PTH occur independently of bone formation. In summary, the
short-term local administration of PTH shows therapeutic potential
as part of a future strategy to regenerate articular cartilage.
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